FDA Phase 2 Approval for Lead Candidate Based on Proprietary Drug Development Platform 'RuCIA', Entering Full-Scale Ensayo Clínicos in the US
RudaCure Inc. (CEO Yongho Kim), una empresa de desarrollo biofarmacéutico especializada en tratamientos de trastornos sensoriales, anunció que ha obtuvo U.S. FDA Phase 2 Investigational New Drug (IND) aprobación for its tratamiento de la enfermedad de ojo seco 'RCI001' on the 24th.
RCI001 is a candidato a nuevo fármaco developed using RudaCure's proprietary AI-based desarrollo de fármacos plataforma 'RuCIA (RudaCure Intelligence for Advanced Drug Development).' It has a mecanismo de acción that suppresses TRPV1 downstream signal-mediated inflammatory activation and is differentiated from existing tratamientos by its powerful antiinflamatorio and efectos antioxidantees.
RudaCure developed RCI001 through the 'RuCIA' plataforma, which combines protein structure analysis, molecular dynamics simulation, and AI-based drug design. La empresa obtuvo U.S. FDA Phase 2 IND aprobación within 5 months of completing Phase 1 ensayo clínicos, demonstrating the efficiency and innovación of this plataforma. It is noteworthy that RuCIA logró this without relying on 'big data AI' requiring massive datasets, instead proving its capability for innovador desarrollo de nuevos fármacos through a 'small data AI' approach combining structural biology-based simulation with machine learning.
Key resultados from Phase 1 ensayo clínicos (realizó on 32 subjects at Chungnam National University Hospital under PI Park Cheol-young) showed no drug-related adverse effects or abnormal findings in vital signs, electrocardiogram, or clinical laboratory tests. Additionally, optimized formulación stability and ocular administration suitability were confirmó. While la empresa's own Phase 1 resultados are not publicly disclosed as it is a listed company and in an unlisted inversión stage, when combined with the Hanlim Pharmaceutical-realizó investigator-initiated ensayo clínico resultados (published), it was confirmó that both signs and symptoms (volumen lagrimal increase + daño corneal recovery) improved simultaneously, with therapeutic effects appearing rapidly within 4 weeks and no efectos secundarios of stinging, burning, or redness upon instillation.
RudaCure planea proceder with Phase 2 ensayo clínicos at major medical instituciones in the US within 2025, and is simultaneously designing Korea's Phase 2 ensayo clínicos with planea begin en el primer semestre de 2026. La empresa también pursuing expansión global based on RCI001's clinical data, including partnering with Thea (France), Santen (Japan), and other global producto farmacéutico oftálmico empresas for licensing and codesarrollo, targeting el mercado global de ojo seco tratamiento mercado proyectoed to exceed $8 billion.
El CEO Yongho Kim declaró: "The FDA Phase 2 IND aprobación signifies that RCI001 ha sido reconocido as a candidato with clear potential for innovador desarrollo de nuevos fármacos, and it is a starting point for full-scale ensayo clínicos in the US." He añadió, "Building on these resultados, we will accelerate global ensayo clínicos and transferencia de tecnología to provide a new tratamiento paradigm for the aproximadamente 350 million ojo seco pacientes worldwide."
